People: Smith & Nephew plc (SNN)
50.24USD
4:04pm EST
$1.14 (+2.32%)
$49.10
$49.65
$50.47
$49.36
124,755
94,200
$53.66
$30.01
Augusti, Mark
Brief Biography
Mark Augusti is President of Biologics of Smith & Nephew Plc. He joined the Group in 2003 as Vice President of Global Marketing for the Trauma Division and became President Orthopaedic Trauma and Clinical Therapies in February 2006. He was appointed to his current role in January 2008. He previously worked for GE Medical Systems in the US and Asia.
Basic Compensation
| Total Annual Compensation, | Long-Term Incentive Plans, | All Other, | Fiscal Year Total, |
|---|---|---|---|
| -- | -- | -- | -- |
Options Compensation
| Quantity | Market Value | |
|---|---|---|
| Excercisable | -- | -- |
| Unexercisable | -- | -- |
| Excercised | -- | -- |
| Name | Fiscal Year Total |
|---|---|
| Buchanan, John | 350,000 |
| Illingworth, David | 1,613,000 |
| Hennah, Adrian | 1,166,000 |
| Augusti, Mark | -- |
| Woody, Joe | -- |
| Frazzette, Michael | -- |
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
